{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T11:06:16Z","timestamp":1789729576526,"version":"4.0.1"},"reference-count":85,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    <jats:italic>In vivo<\/jats:italic>\n                    CAR-T cell generation is advancing rapidly within gene and cell therapy, but it is often framed as an \u201cin-body\u201d version of\n                    <jats:italic>ex vivo<\/jats:italic>\n                    CAR-T\u2014a view that obscures fundamental pharmacological differences. We propose that\n                    <jats:italic>in vivo<\/jats:italic>\n                    CAR-T is better understood as a vector-to-cell pharmacological transition, in which vector pharmacology directly shapes cellular pharmacology: vector dose is only the administered input, whereas therapeutic cellular exposure is hypothesized to depend jointly on the rate, duration, and functional quality of CAR-T cells generated within the patient. Three generation-phase constraints \u2014 niche competition without lymphodepletion, founding-state lock-in, and antigen-encounter timing mismatch \u2014 define this transition and inform platform\u2013indication matching. We develop this as a testable organizing hypothesis rather than a validated pharmacokinetic model, specifying which quantities are observed, which are inferred, and which are derived, together with four falsifiable predictions and the measurements required to evaluate them. \u201cProduction rate \u00d7 functional window\u201d is retained as a mnemonic for the two axes involved \u2014 the kinetics and duration of cellular generation, and the functional quality of the cells generated \u2014 rather than as an arithmetic product.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2026.1939127","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T10:53:21Z","timestamp":1789728801000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["In vivo CAR-T cell generation: a production-rate framework linking vector and cellular pharmacology"],"prefix":"10.3389","volume":"17","author":[{"given":"Jing","family":"Hu","sequence":"first","affiliation":[{"name":"Zhengzhou Advanced Research Institute, Harbin Institute of Technology","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dandan","family":"Zhu","sequence":"additional","affiliation":[{"name":"Henan Shenyou Medical Laboratory Co., Ltd","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanliang","family":"Zheng","sequence":"additional","affiliation":[{"name":"School of Life Science and Technology, Harbin Institute of Technology","place":["Harbin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-021-00635-3","article-title":"Balancing quality, cost, and access during delivery of newer cellular and immunotherapy treatments","volume":"16","author":"Geethakumari","year":"2021","journal-title":"Curr Hematol Malig Rep"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2024.101250","article-title":"CAR-T cell manufacturing landscape\u2014lessons from the past decade and considerations for early clinical development","volume":"32","author":"Dias","year":"2024","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.3390\/ijms27041737","article-title":"In vivo CAR-T therapies-a new era of programmable immunity","volume":"27","author":"Pierini","year":"2026","journal-title":"Int J Mol Sci"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102353","article-title":"CAR-T cells in solid tumors: challenges and breakthroughs","volume":"6","author":"Escobar","year":"2025","journal-title":"Cell Rep Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s40164-025-00725-5","article-title":"In vivo CAR-T cell engineering: concept, research progress, potential challenges and enhancement strategies","volume":"14","author":"Chen","year":"2025","journal-title":"Exp Hematol Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2026.101028","article-title":"Current state of CAR-T cell therapies for solid tumors","volume":"7","author":"Rosa","year":"2026","journal-title":"Med (N Y)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.103941","article-title":"Improving CAR-T immunotherapy: overcoming the challenges of T cell exhaustion","volume":"77","author":"Gumber","year":"2022","journal-title":"EBioMedicine"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1126\/science.abm0594","article-title":"CAR T cells produced in vivo to treat cardiac injury","volume":"375","author":"Rurik","year":"2022","journal-title":"Science"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1126\/science.ads8473","article-title":"In vivo CAR T cell generation to treat cancer and autoimmune disease","volume":"388","author":"Hunter","year":"2025","journal-title":"Science"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)01030-X","article-title":"In-vivo B-cell maturation antigen CAR T-cell therapy for relapsed or refractory multiple myeloma","volume":"406","author":"Xu","year":"2025","journal-title":"Lancet"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-026-04244-6","article-title":"In vivo generation of anti-BCMA CAR-T cells in relapsed or refractory multiple myeloma: a phase 1 study","volume":"32","author":"An","year":"2026","journal-title":"Nat Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-lba-1","article-title":"Minimal residual disease (MRD)-negative outcomes following a novel, in vivo gene therapy generating anti-BCMA chimeric antigen receptor (CAR)-T cells in patients with relapsed and refractory multiple myeloma (RRMM): preliminary results from inMMyCAR, the first-in-human phase 1 study of KLN-1010","volume":"146","author":"Harrison","year":"2025","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-026-10235-x","article-title":"In vivo site-specific engineering to reprogram T cells","volume":"652","author":"Nyberg","year":"2026","journal-title":"Nature"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-25-3748","article-title":"Optimizing In vivo CAR-T cell engineering for cancer immunotherapy","volume":"86","author":"Wang","year":"2026","journal-title":"Cancer Res"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibtech.2025.11.006","article-title":"Clinical technology advances driving in vivo CAR therapy","volume":"44","author":"Li","year":"2026","journal-title":"Trends Biotechnol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.bict.2025.100027","article-title":"In vivo generation of CAR T cells: biology, delivery platforms, clinical promise, and translational challenges","volume":"2","author":"Volta","year":"2026","journal-title":"Blood Immunol Cell Ther"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-025-01174-1","article-title":"In vivo CAR engineering for immunotherapy","volume":"25","author":"Li","year":"2025","journal-title":"Nat Rev Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2024.03.004","article-title":"Direct in vivo CAR T cell engineering","volume":"45","author":"Short","year":"2024","journal-title":"Trends Pharmacol Sci"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00921","article-title":"Regulatory framework for advanced therapy medicinal products in Europe and United States","volume":"10","author":"Iglesias-Lopez","year":"2019","journal-title":"Front Pharmacol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2986","article-title":"Best practices and considerations for clinical pharmacology and pharmacometric aspects for optimal development of CAR-T and TCR-T cell therapies: an industry perspective","volume":"114","author":"Mody","year":"2023","journal-title":"Clin Pharmacol Ther"},{"key":"B22","article-title":"Long term follow-up after administration of human gene therapy products: guidance for industry","volume-title":"Center for Biologics Evaluation and Research","year":"2020"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/nri1052","article-title":"Cytokine control of memory T-cell development and survival","volume":"3","author":"Schluns","year":"2003","journal-title":"Nat Rev Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20050732","article-title":"Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells","volume":"202","author":"Gattinoni","year":"2005","journal-title":"J Exp Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T cell exhaustion","volume":"15","author":"Wherry","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/nature22367","article-title":"Chromatin states define tumour-specific T cell dysfunction and reprogramming","volume":"545","author":"Philip","year":"2017","journal-title":"Nature"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1325-x","article-title":"TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion","volume":"571","author":"Khan","year":"2019","journal-title":"Nature"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1326-9","article-title":"TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection","volume":"571","author":"Alfei","year":"2019","journal-title":"Nature"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1324-y","article-title":"TOX is a critical regulator of tumour-specific T cell differentiation","volume":"571","author":"Scott","year":"2019","journal-title":"Nature"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.cir-14-0186","article-title":"Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells","volume":"3","author":"Frigault","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3838","article-title":"4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors","volume":"21","author":"Long","year":"2015","journal-title":"Nat Med"},{"key":"B32","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.celrep.2017.09.015","article-title":"Tonic 4-1BB costimulation in chimeric antigen receptors impedes T cell survival and is vector-dependent","volume":"21","author":"Gomes-Silva","year":"2017","journal-title":"Cell Rep"},{"key":"B33","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s40364-026-00899-y","article-title":"In vivo engineering of CAR-T cells: delivery strategies and clinical translation","volume":"14","author":"Gao","year":"2026","journal-title":"biomark Res"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat Rev Mater"},{"key":"B35","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/s41578-022-00529-7","article-title":"Passive, active and endogenous organ-targeted lipid and polymer nanoparticles for delivery of genetic drugs","volume":"8","author":"Dilliard","year":"2023","journal-title":"Nat Rev Mater"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006292","article-title":"Preclinical proof of concept for VivoVec, a lentiviral-based platform for in vivo CAR T-cell engineering","volume":"11","author":"Michels","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024523","article-title":"In vivo CAR T-cell generation in nonhuman primates using lentiviral vectors displaying a multidomain fusion ligand","volume":"144","author":"Nicolai","year":"2024","journal-title":"Blood"},{"key":"B38","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12943-025-02515-3","article-title":"Next-generation CAR-T cells design: leveraging tumor features for enhanced efficacy","volume":"25","author":"Lei","year":"2026","journal-title":"Mol Cancer"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1698442","article-title":"Engineering the next generation of CAR T-cells: precision modifications, logic gates and universal strategies to overcome exhaustion and tumor resistance","volume":"15","author":"Garcia-Robledo","year":"2026","journal-title":"Front Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17172898","article-title":"Advancing CAR T-cell therapy in solid tumors: current landscape and future directions","volume":"17","author":"Rafii","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1652329","article-title":"Challenges and breakthroughs: current landscape and future prospects of CAR-T cell therapy clinical trials for solid tumors","volume":"15","author":"Guo","year":"2025","journal-title":"Front Oncol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/s41419-018-0278-6","article-title":"CAR-T cells: the long and winding road to solid tumors","volume":"9","author":"D'Aloia","year":"2018","journal-title":"Cell Death Dis"},{"key":"B43","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s00262-025-04278-8","article-title":"Unleashing CAR-T potential in solid tumors: overcoming intrinsic and extrinsic hurdles to improve therapy","volume":"75","author":"Zhang","year":"2026","journal-title":"Cancer Immunol Immunother"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1755751","article-title":"T cell immunotherapy for solid tumors: limitations, progress, and future prospects","volume":"17","author":"Wang","year":"2026","journal-title":"Front Immunol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-021-00244-2","article-title":"Dual targeting CAR-T cells with optimal costimulation and metabolic fitness enhance antitumor activity and prevent escape in solid tumors","volume":"2","author":"Hirabayashi","year":"2021","journal-title":"Nat Cancer"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1643941","article-title":"Current strategies for armoring chimeric antigen receptor T-cells to overcome barriers of the solid tumor microenvironment","volume":"16","author":"Yang","year":"2025","journal-title":"Front Immunol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s40164-024-00564-w","article-title":"Therapeutic targets of armored chimeric antigen receptor T cells navigating the tumor microenvironment","volume":"13","author":"Li","year":"2024","journal-title":"Exp Hematol Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2022.12.022","article-title":"An evolved AAV variant enables efficient genetic engineering of murine T cells","volume":"186","author":"Nyberg","year":"2023","journal-title":"Cell"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2004.12.003","article-title":"Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy","volume":"26","author":"Klebanoff","year":"2005","journal-title":"Trends Immunol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00924","article-title":"Dendritic cells and their role in immunotherapy","volume":"11","author":"Gardner","year":"2020","journal-title":"Front Immunol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-00490-y","article-title":"Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity","volume":"21","author":"Veglia","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/nrd4597","article-title":"The pharmacology of second-generation chimeric antigen receptors","volume":"14","author":"van der Stegen","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/s41551-021-00842-6","article-title":"Rapid manufacturing of non-activated potent CAR T cells","volume":"6","author":"Ghassemi","year":"2022","journal-title":"Nat BioMed Eng"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-05-431718","article-title":"IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors","volume":"121","author":"Cieri","year":"2013","journal-title":"Blood"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2446","article-title":"A human memory T cell subset with stem cell-like properties","volume":"17","author":"Gattinoni","year":"2011","journal-title":"Nat Med"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2009.182","article-title":"Prevalence of serum IgG and neutralizing factors against AAV types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors","volume":"21","author":"Boutin","year":"2010","journal-title":"Hum Gene Ther"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/nm1549","article-title":"CD8(+) T-cell responses to adeno-associated virus capsid in humans","volume":"13","author":"Mingozzi","year":"2007","journal-title":"Nat Med"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2019.12.010","article-title":"AAV vector immunogenicity in humans: a long journey to successful gene transfer","volume":"28","author":"Verdera","year":"2020","journal-title":"Mol Ther"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1038\/nnano.2017.57","article-title":"In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers","volume":"12","author":"Smith","year":"2017","journal-title":"Nat Nanotechnol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"6080","DOI":"10.1038\/s41467-020-19486-2","article-title":"In vitro-transcribed antigen receptor mRNA nanocarriers for transient expression in circulating T cells in vivo","volume":"11","author":"Parayath","year":"2020","journal-title":"Nat Commun"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1038\/s41565-020-0669-6","article-title":"Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing","volume":"15","author":"Cheng","year":"2020","journal-title":"Nat Nanotechnol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/s41392-025-02512-4","article-title":"Scarless circular mRNA-based CAR-T cell therapy elicits superior antitumor efficacy","volume":"10","author":"Hu","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abf1333","article-title":"A nonviral, nonintegrating DNA nanovector platform for the safe, rapid, and persistent manufacture of recombinant T cells","volume":"7","author":"Bozza","year":"2021","journal-title":"Sci Adv"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2017.207","article-title":"Preclinical efficacy and safety of CD19CAR cytokine-induced killer cells transfected with Sleeping Beauty transposon for the treatment of acute lymphoblastic leukemia","volume":"29","author":"Magnani","year":"2018","journal-title":"Hum Gene Ther"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-011759","article-title":"T cell-specific non-viral DNA delivery and in vivo CAR generation using targeted lipid nanoparticles","volume":"13","author":"Bimbo","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B66","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/s41408-021-00508-1","article-title":"AAV-mediated in vivo CAR gene therapy for targeting human T-cell leukemia","volume":"11","author":"Nawaz","year":"2021","journal-title":"Blood Cancer J"},{"key":"B67","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.immuni.2025.01.009","article-title":"In vivo engineering of murine T cells using the evolved adeno-associated virus variant Ark313","volume":"58","author":"Nyberg","year":"2025","journal-title":"Immunity"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1038\/nature21405","article-title":"Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection","volume":"543","author":"Eyquem","year":"2017","journal-title":"Nature"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-11-4564","article-title":"An inducible caspase 9 safety switch for T-cell therapy","volume":"105","author":"Straathof","year":"2005","journal-title":"Blood"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1106152","article-title":"Inducible apoptosis as a safety switch for adoptive cell therapy","volume":"365","author":"Di Stasi","year":"2011","journal-title":"N Engl J Med"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-022-00825-x","article-title":"Impact of anti-PEG antibodies induced by SARS-CoV-2 mRNA vaccines","volume":"23","author":"Ju","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-786129","article-title":"Cellular kinetics of CTL019 in relapsed\/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia","volume":"130","author":"Mueller","year":"2017","journal-title":"Blood"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12388","article-title":"Tisagenlecleucel model-based cellular kinetic analysis of chimeric antigen receptor\u2013T cells","volume":"8","author":"Stein","year":"2019","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12636","article-title":"Quantitative systems pharmacology model of chimeric antigen receptor T-cell therapy","volume":"12","author":"Hardiansyah","year":"2019","journal-title":"Clin Transl Sci"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1159\/000525052","article-title":"Treatment with living drugs: Pharmaceutical aspects of CAR T cells","volume":"107","author":"Holzinger","year":"2022","journal-title":"Pharmacology"},{"key":"B77","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41540-024-00355-3","article-title":"Making drugs from T cells: The quantitative pharmacology of engineered T cell therapeutics","volume":"10","author":"Kirouac","year":"2024","journal-title":"NPJ Syst Biol Appl"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002394","article-title":"Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Locke","year":"2020","journal-title":"Blood Adv"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2022.114421","article-title":"Cellular kinetics: A clinical and computational review of CAR-T cell pharmacology","volume":"188","author":"Qi","year":"2022","journal-title":"Adv Drug Delivery Rev"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17193216","article-title":"Eliminating REMS for CAR T-Cell Therapies: An opportunity to improve access","volume":"17","author":"Orosco-Ttamina","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.3703","article-title":"FDA experience on CAR T cell pharmacokinetics\/pharmacodynamics and model-based assessments","volume":"118","author":"Tegenge","year":"2025","journal-title":"Clin Pharmacol Ther"},{"key":"B83","article-title":"Considerations for the development of chimeric antigen receptor (CAR) T cell products: guidance for industry","volume-title":"Center for Biologics Evaluation and Research","year":"2024"},{"key":"B84","doi-asserted-by":"publisher","first-page":"7014","DOI":"10.1200\/JCO.2026.44.16_suppl.7014","article-title":"First-in-human in vivo CAR T-cell generation using a CD8-targeted lipid nanoparticle platform in relapsed\/refractory B-cell lymphoma","volume":"44","author":"Zhang","year":"2026","journal-title":"J Clin Oncol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2026.03.033","article-title":"In situ generation of EBNA1 CAR-T cells eradicates antigen specific auto-immune B cells for multiple sclerosis treatment","volume":"16","author":"Shi","year":"2026","journal-title":"Acta Pharm Sin B"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1939127\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T10:53:23Z","timestamp":1789728803000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1939127\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,18]]},"references-count":85,"alternative-id":["10.3389\/fimmu.2026.1939127"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1939127","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,18]]},"article-number":"1939127"}}